[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350251-105":59,"doc-detail-350251-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","nrg1-fusion-positive-solid-tumors-article-clinical-detection-genomic-landscape-and-real-world-data-in-pancreatic-cancer","NRG1 fusion-positive solid tumors - Article - clinical detection, genomic landscape, and real-world data in pancreatic cancer","","NRG1 fusions are described as distinctive oncogenic drivers that activate the HER3/HER2/PI3K signaling pathway, with regulatory momentum led by accelerated approval of a HER2/HER3 antibody for NRG1 fusion-positive disease. However, detection performance and clinicopathological characteristics have not been systematically assessed. Using Memorial Sloan Kettering Cancer Center records, the study reviews clinical, radiology, and pathology features and evaluates outcomes, with a focus on pancreatic ductal adenocarcinoma.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nrg1-fusion-positive-solid-tumors-article-clinical-detection-genomic-landscape-and-real-world-data-in-pancreatic-cancer/350251/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nrg1-fusion-positive-solid-tumors-article-clinical-detection-genomic-landscape-and-real-world-data-in-pancreatic-cancer/350251.png","ImageObject",300,407,{"name":92,"@type":93},"Bintang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main focus of the study on NRG1 fusion-positive cancers?","Question",{"text":113,"@type":114},"The study reviews NRG1 fusion-positive cancer and emphasizes outcomes and defining features in pancreatic ductal adenocarcinoma (PDAC).","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were NRG1 fusion-positive patients identified and what data were reviewed?",{"text":118,"@type":114},"Patients were identified from institutional databases, clinicopathological data were extracted from medical records, and NRG1 fusion-positive PDAC cases underwent review of radiology, pathology, treatment information, and survival outcomes.",{"name":120,"@type":111,"acceptedAnswer":121},"Which detection approach performed better for fusion identification in this dataset?",{"text":122,"@type":114},"RNA-based detection was superior to DNA-based detection for identifying NRG1 fusions.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},350251,1790135206,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085564381,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","JNCI: Journal of the National Cancer Institute, 2026, 118(5), 847–855  \n[https://doi.org/10.1093/jnci/djaf361](https://doi.org/10.1093/jnci/djaf361)  \nAdvance Access Publication Date: December 13, 2025  \nArticle  \nNRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancer  \nAlison M. Schram , MD􀀃 ,1 , Soo-Ryum Yang , MD2, Genessa Kahn 1, 3, Rogelio Velasco , MD4, Matteo Repetto, MD1, Richard Kinh Gian Do , MD, PhD5, Sara DiNapoli, PhD2, Purvil Sukhadia, MS2, Megan Troxel , MS1, Kerem Ozcan , MD2, Zeynep Tarcan , MD2, Marc Ladanyi , MD2, James J. Harding , MD1, Alexander Drilon , MD1, Olca Basturk , MD2, Eileen M. O’Reilly , MD1  \n1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA  \n2Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA 3Hunter College, New York, NY 10065, USA  \n4Department of Thoracic Oncology, Lung Center of the Philippines, Quezon City 1100, Philippines 5Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA  \n􀀃 Corresponding author: Alison M. Schram, MD, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065-6007, United States ([schrama@mskcc.org](schrama@mskcc.org)) .  \nAuthor Contributions: Drs A. M. Schram and S. R. Yang are considered co–first authors. Drs O. Basturk and E. M. O’Reilly are considered co–last authors.  \nAbstract  \nBackground: NRG1 fusions are unique oncogenic drivers that activate the HER3/HER2/PI3K pathway. The US Food and Drug Administration granted accelerated approval to a HER2/HER3 antibody, zenocutuzumab, for treatment of NRG1 fusion-positive non– small cell lung cancer and pancreatic ductal adenocarcinoma (PDAC) . The optimal detection methods and clinicopathological features of patients with NRG1 fusion-positive cancer have not been systematically studied. Here, we review NRG1 fusion-positive cancer and focus on outcomes in PDAC.  \nMethods: Patients with NRG1 fusion-positive disease at Memorial Sloan Kettering Cancer Center were identified using institutional databases. Clinicopathological data were extracted from medical records. NRG1 fusion-positive PDAC cases underwent review of radiology, pathology, treatment data, and assessment of progression-free and overall survival.  \nResults: Of 76 531 patients, 48 NRG1 fusion-positive cases were identified. The most common tumor types were lung (60%), PDAC (21%), and breast (10%). Approximately half (46%) of these patients received HER2-and/or HER3-directed therapy. Patients were identified by RNA (n ¼ 34), DNA (n ¼ 11), or both (n ¼ 3) . RNA was superior to DNA for fusion identification. Twenty-one fusion partners were detected, most commonly CD74 (40%) and ATP1B1 (10%) . Lung cancers were otherwise driver negative, and PDAC cases were KRAS wild type. NRG1 fusion-positive PDAC exhibited distinct histopathological and clinical features. Median patient age was 48.5 years, median progression-free survival on first-line chemotherapy was 12.6 months (n ¼ 7; 95% confidence interval [CI] ¼ 2.9 to not reached), and median overall survival from diagnosis was 39.6 months (n ¼ 9; 95% CI ¼ 23.2 to not reached) .  \nConclusions: NRG1 fusions are a newly described, clinically actionable target in solid tumors. We report the landscape of NRG1 fusion-positive cancers and highlight the importance of RNA testing. NRG1 fusion-positive PDAC is enriched in younger patients with KRAS wild-type disease and has unique biology.  \nIntroduction  \nGene fusions occur across solid tumors and typically drive oncogenesis through constitutive activation of tyrosine kinases, increased downstream signaling, and uncontrolled tumor growth. Small molecule inhibitors targeting fusions involving ALK, ROS1, RET, and TRK have demonstrated remarkable activity across several cancer types, transforming the treatment paradigm and  \nimproving prognosis fo","cbCaiiXXvNQGYBCL","https://ap.wps.com/l/cbCaiiXXvNQGYBCL","pdf",1316195,"English","# Background\n# Methods\n# Results\n## Patient identification and detection methods\n## Tumor spectrum and key fusion partners\n## Clinicopathological findings in PDAC\n# Conclusions","[{\"question\":\"What is the main focus of the study on NRG1 fusion-positive cancers?\",\"answer\":\"The study reviews NRG1 fusion-positive cancer and emphasizes outcomes and defining features in pancreatic ductal adenocarcinoma (PDAC).\"},{\"question\":\"How were NRG1 fusion-positive patients identified and what data were reviewed?\",\"answer\":\"Patients were identified from institutional databases, clinicopathological data were extracted from medical records, and NRG1 fusion-positive PDAC cases underwent review of radiology, pathology, treatment information, and survival outcomes.\"},{\"question\":\"Which detection approach performed better for fusion identification in this dataset?\",\"answer\":\"RNA-based detection was superior to DNA-based detection for identifying NRG1 fusions.\"}]","NRG1 fusion-positive solid tumors - Article - clinical detection, genomic landscape, and real-world data in pancreatic cancer | PDF",1790088045,23,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/64db6f70a0ca03ff9b61f0cebcd6fb23.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7e13925030873965c9c53b69675446db.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7afb553faf85a57280f0818a8cc9cf6c.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9f607f0c5df07f3136d8148ea7944d84.webp",980,1287]